Background. There is strong evidence linking inflammation and the development of pancreatic ductal adenocarcinoma. Cyclooxygenase-2 (COX-2) and COX-2-derived PGE 2 are overexpressed in human and murine pancreatic ductal adenocarcinoma. Several studies have demonstrated an important role of COX-2-derived PGE 2 in tumor-stroma interactions; however, the direct growth effects of prostaglandin E 2 (PGE 2 ) on pancreatic ductal adenocarcinoma cells is less well defined. Our aim was to investigate the effects of PGE 2 on pancreatic ductal adenocarcinoma cell growth and to characterize the underlying mechanisms. Methods. Human pancreatic ductal adenocarcinoma cell lines, Panc-1 and MIA PaCa-2, were treated with PGE 2 in varying doses (0-10 mM). Effects on the phosphorylation of ERK1/2 were evaluated by Western blot. Colony formation was observed for cells treated with PGE 2 for 11 days. DNA synthesis was determined by (3H)-thymidine incorporation assay. Gene expression of E-type prostaglandin (EP)2/EP4 receptors and their correlation with survival in patients with pancreatic ductal adenocarcinoma were assessed using the RNA-Seq data set from The Cancer Genome Atlas Research Network. Results. PGE 2 decreased the size and number of colonies in Panc-1 but not MIA PaCa-2 cells. In the Panc-1 cells, PGE 2 activated PKA/CREB and decreased phosphorylation of ERK1/2, which was reversed by an EP4 receptor antagonist, while an EP2 receptor antagonist had no effect. In contrast, in MIA PaCa-2 cells, PGE 2 had no effect on ERK1/2 phosphorylation. Treatment of both Panc-1 and MIA PaCa-2 cells with forskolin/IBMX decreased ERK1/2 phosphorylation. Finally, PGE 2 decreased DNA synthesis only in Panc-1 cells, which was reversed by an EP4 receptor antagonist. In human pancreatic ductal adenocarcinoma, high EP2 and low EP4 gene expression was correlated to worse median overall survival (15.6 vs 20.8 months, log-rank P = .017). Conclusion. Our study provides evidence that PGE 2 can inhibit directly pancreatic ductal adenocarcinoma cell growth through an EP4-mediated mechanism. Together with our gene expression and survival analysis, this observation suggests a protective role of EP4 receptors in human pancreatic ductal adenocarcinoma that expresses E-type prostaglandin receptors. (Surgery 2017;161:1570-8.) 
AS IN MANY OTHER MALIGNANCIES, inflammation has been linked to pancreatic ductal adenocarcinoma (PDAC) as being protumorigenic and a major contributor not only to cancer development but also to maintaining a tumor environment that further enhances tumor growth and invasion. 1, 2 Studies have shown that cyclooxygenase 2 (COX-2) is overexpressed in various malignancies [3] [4] [5] [6] [7] [8] and that the mechanism by which COX-2 enhances cancer development includes conversion of the omega-6 polyunsaturated fatty acid arachidonic acid (20:4w6) into 2-series prostanoids.
The most abundant 2-series prostanoid in many malignancies is prostaglandin E 2 (PGE 2 ). 9 Similar to COX-2 overexpression, 10 PGE 2 was found to be increased 11 and to promote tumor growth and invasiveness in PDAC 12, 13 and other malignancies. [14] [15] [16] [17] [18] Selective COX-2 inhibitors and microRNA-143 showed the capacity to inhibit growth of COX-2-expressing PDAC by affecting PGE 2 synthesis. [19] [20] [21] Moreover, selective COX-2-inhibitors can attenuate the progression of pancreatic intraepithelial neoplasia, which are known precursor lesions of PDAC. 22 The cellular effects of PGE 2 are mediated via membranous E-type prostaglandin (EP) receptors, G protein-coupled receptors, which are classified into 4 subtypes, named EP receptors 1 through 4 (EP1-4). 23, 24 The EP1 receptor couples to Ga q and signals through inositol trisphosphate and calcium (Ca 2+ )-dependent pathways. The EP3 receptor is coupled to Ga i , inhibits adenylyl cyclase, and decreases intracellular levels of cAMP, while EP2 and EP4, both linked to Ga s , stimulate adenylate cyclase and increase cAMP leading to activation of protein kinase A (PKA) and exchange protein activated by cAMP (Epac).
In addition, EP4 but not EP2 can also signal through Ga i leading to inhibition of (Ga i -sensitive) adenylyl cyclase isoforms. 25 In cancer, EP1, but even more EP2 and EP4, have been associated to tumor progression and invasiveness. [26] [27] [28] [29] In PDAC, PGE 2 , acting through EP2 and EP4, enhances stromal vascularization by increasing the production of vascular endothelial growth factor (VEGF) 30 in cancer cells and promotes fibrosis through activation of pancreatic stellate cells. 31 As a proinflammatory mediator, PGE 2 also increases T-cell invasion 18 and matrix metalloproteinase-9 13 in the tumor-microenvironment and promotes resistance to chemotherapy by interleukin-1 beta-expression from mononuclear cells. 32 Overall, the protumorigenic effects of the PGE 2 /EP-receptor signaling axis involve modulating the tumor environment. The direct impact of PGE 2 on PDAC cell growth is less well understood. There is limited evidence for an antiapoptotic effect through COX-2-derived PGE 2 in PDAC cells. 33 We reported previously the EP receptor expression in a panel of human PDAC cell lines. 34 Panc-1 was found to have high mRNA expression of EP2 and EP4 receptors, while MIA PaCa-2 cells display relatively low levels of both receptors.
Our aim of the present study was to investigate the direct effects of PGE 2 on the cell growth of several tumor cell lines of PDAC. We chose Panc-1 and MIA PaCa-2 cells because they represent 2 human PDAC cell lines with different expression levels of EP2/EP4 receptors. We found that PGE 2 has a direct growth inhibitory effect in human PDAC cell lines in vitro through an EP4-mediated mechanism.
MATERIALS AND METHODS
Cell culture. The human PDAC cell lines, Panc-1 (CRL-1469) and MIA PaCa-2 (MP2; CRL-1420), both of which harbor mutations in Kras and p53, were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and grown in Dulbecco's modified Eagle Medium (Life Technologies, Carlsbad, CA) containing 25 mM D-glucose, 4 mM glutamine, 1 mM sodium pyruvate, 1% Penicillin G, and 10% fetal bovine serum (FBS). The cells were kept at 378C in a humidified atmosphere containing 10% CO 2 .
Colony formation assay. To monitor human PDAC cell growth in the presence or absence of PGE 2 , colony growth of Panc-1 and MP2 was recorded over 10 to 12 days. Briefly, 250 cells of each cell line were seeded onto 6-cm dishes containing DMEM with 10% FBS (in triplicates). After 24 hours, cells were cultured in serum-free medium for 6 hours. Cells were then exposed to PGE 2 (Cayman Chemical Company, Ann Arbor, MI) (0-10 mM) in medium containing 3% FBS. PGE 2 was added every 24 hours. After 11 days, cells were fixed with 10% buffered formalin phosphate and stained with Giemsa. Images were taken with FujiFilm ImageQuant LAS 4000 (GE Healthcare Sciences, Pittsburgh, PA) and analysis performed with the open-source, cell image analysis software CellProfiler, version 2.1.1 (www.cellprofiler.org). 35 (3H)-thymidine incorporation assay. Cells were treated with the indicated compounds overnight. Treatment groups were as follows (all agents were obtained from Cayman Chemical Company, Ann Arbor, MI): vehicle control, PGE 2 (1 mM), EP4 receptor antagonist L-161,982 (1 mM), EP2 receptor antagonist PF-04418948 (10 mM), forskolin (10 mM) and IBMX (100 mM), and various combinations. The next day, (3H)-thymidine (0.25 mCi/ mL) was added to each well and incubated for 6 hours. Then, the medium containing the radioactive label was removed and the cells washed twice with PBS. Cells were fixed with trichloroacetic acid (5%), washed with 70% ethanol, and lysed with 0.1 N NaOH before being transferred to a liquid scintillation counter.
Western blotting. Panc-1 and MP2 cells were seeded to 6-well plates (4 3 10 5 cells per well) and after 24 hours serum-starved with serum-free DMEM overnight. Treatment was performed by adding the indicated compounds in serum-free medium. Cells were lysed and the protein concentration was measured (BCA Protein Assay Kit; Thermo Scientific, Rockford, IL). Equal protein amounts were added to precast gels (Mini-Protean TGX Precast Gels; Bio-Rad Laboratories, Hercules, CA). Protein transfer to supported nitrocellulose membranes (Bio-Rad) was performed using transfer buffer containing 20 % methanol. Membranes were blocked using 5% skim milk, washed with 1% tween-TBS (Tris buffered saline), and incubated with the primary antibody overnight.
The following primary antibodies were used (all from Cell Signaling Technologies, Danvers, MA): phospho-ERK (phospho-p44/42 Erk1/2, Thr202/ Tyr204), total ERK (p44/42), phospho-CREB (Ser133), and GAPDH. Membranes were incubated with the secondary antibodies, and proteins were visualized using the enhanced chemiluminescent substrate kit (SuperSignal West Pico Chemiluminescent Substrate or SuperSignal West Femto Maximum Sensitivity Substrate; Thermo Scientific). Images were taken by the ChemiDoc Touch Imaging System (Bio-Rad).
EP2 and EP4 gene expression analysis in human PaCa. Gene expression for EP2 (PTGER2), EP4 (PTGER4), and membrane-associated prostaglandin E synthase-2 (PTGES2) on patient samples was obtained from the publicly available pancreatic adenocarcinoma gene expression by RNAseq (TCGA_PAAD_exp_HiSeqV2) data set from The Cancer Genome Atlas (TCGA). Fully processed data on gene expression and clinicopathologic information from the TCGA data set were obtained using the UC Santa Cruz (UCSC) Cancer Genomics Browser. Briefly, for the wrangling procedure, Level_3 Data (file names: *.rsem.genes.normalized_results) were downloaded from the TCGA Data Coordination Center, log2(x+1) transformed, and processed at UCSC into cgData repository by the Cancer Browser Team (cgData TCGAscript RNAseq processed on 2015-01-27).
Gene-level transcription estimates were based on the RSEM (RNA-Seq by Expectation Maximization) software package (deweylab.github.io/ RSEM/). For patient dichotomization, k-means clustering was performed whereby each tumor was segregated into low-or high-expression groups based on its relationship to the nearest of 2 means. Statistical analyses were performed using SPSS software (version 23.0; IBM Corp, Armonk, NY) software. Fisher exact tests were used to evaluate the relationship between dichotomized patient groups and clinical variables. Kaplan-Meier survival curves were evaluated by the log-rank test.
RESULTS
PGE 2 decreased colony growth of Panc-1 but not MIA PaCa-2 cells in vitro. The effect of PGE 2 (0-10 mM) on cell growth was assessed by colony formation assays. PGE 2 decreased dose dependently the numbers of Panc-1 colonies (PGE 2 1 mM vs 0 mM: 74 ± 10 colonies vs 96 ± 3 colonies; P < .001; Fig 1, A) . Similar results were seen when comparing the total area covered by Panc-1 colonies, although significance was only observed at 10 mM PGE 2 (PGE 2 10 mM vs 0 mM: 4,401 ± 779 pixel/dish vs 14,635 ± 1,962 pixel/dish; P < .05). PGE 2 had no significant effect on MIA PaCa-2 colony formation (Fig 1, B) as measured by colony numbers and total colony area (eg, PGE 2 10 mM vs 0 mM: 37,663 ± 14,749 pixel/dish vs 47,625 ± 9,452 pixel/dish; P > .05).
PGE 2 inhibited phosphorylation of ERK1/2 in Panc-1 cells via protein kinase A. To determine Total ERK was used as the loading control. (B) Panc-1 and MIA PaCa-2 cells were exposed to PGE 2 or forskolin/ IBMX and ERK1/2 (Thr202/Tyr204) phosphorylation was evaluated. Total ERK was used as loading control. (C) Panc-1 and MIA PaCa-2 cells were exposed to PGE 2 in the presence or absence of the PKA inhibitor H89 and ERK1/2 (Thr202/Tyr204) phosphorylation was evaluated. GAPDH was used as the loading control. P-CREB was used as a measure for PKA activation. the signaling pathways underlying the growthinhibitory effects of PGE 2 in Panc-1 cells, we first evaluated the extracellular-signal regulated kinase (ERK1/2) pathway, a major growth-stimulating module in PDAC. 35, 36 In Panc-1 cells, PGE 2 at 1 and 10 mM decreased time dependently phosphorylation of ERK1/2 (Fig 2, A) . A significant decrease in pERK1/2 was seen already at 15 minutes and disappeared after 60 minutes. PGE 2 had no significant effect on pERK1/2 in MIA PaCa-2 cells (Fig  2, A) .
PGE 2 binds to EP receptors, which can activate protein kinase A (PKA). To assess whether the effect of PGE 2 on ERK1/2 phosphorylation was mediated by PKA, we first used forskolin, which activates directly adenylyl cyclase with a subsequent increase in intracellular cAMP levels leading to activation of PKA. 37 In both Panc-1 and MIA PaCa-2 cells, forskolin in the presence of IBMX, a competitive, non-selective phosphodiesterase inhibitor that decreases the breakdown of cAMP, 38 decreased pERK1/2 to almost nondetectable levels (Fig 2, B) .
Second, we used the pharmacologic PKA inhibitor H89. Exposure of Panc-1 and MIA PaCa-2 cells to H89 alone increased pERK1/2. In addition, H89 at 5 mM reversed completely the inhibitory effects of PGE 2 on pERK1/2 in Panc-1 cells (Fig 2,  C) . In MIA PaCa-2 cells, the combination of H89 and PGE 2 had a similar effect on ERK1/2 phosphorylation as H89 alone (Fig 2, C) . Inhibition of PKA by H89 at 5 mM was confirmed by evaluating levels of phosphorylated CREB (cAMP response element-binding protein), a downstream target of PKA. 39 Exposure of Panc-1 cells to PGE 2 led to activation of CREB, which was attenuated by 5 mM H89 (Fig 2, C) .
The inhibitory effect of PGE 2 on ERK1/2 phosphorylation is mediated by the EP4 receptor. To determine which EP receptor(s) mediates the effects of PGE 2 in Panc-1 cells, we used pharmacologic receptor antagonists. We reported previously that Panc-1 cells express high levels of EP4 and EP2, while MIA PaCa-2 displayed relative low levels of both receptors. 34 In Panc-1 cells, the selective EP4 receptor antagonist L-161,982 increased phosphorylation of ERK1/2. In addition, L-161,982 reversed completely the inhibitory effects of PGE 2 on ERK1/2 phosphorylation (Fig 3) . In contrast, the selective EP2 receptor antagonist PF-04418948 had no effect on PGE 2 -mediated inhibition of ERK1/2 phosphorylation (Fig 3) . Moreover, in MIA PaCa-2, neither the EP4 nor the EP2 receptor antagonist affected ERK1/2 phosphorylation (Fig 3) .
PGE2 decreased DNA synthesis in Panc-1 cells through the EP4 receptor. Having demonstrated that PGE 2 inhibited ERK1/2 phosphorylation through EP4-mediated activation of PKA in Panc-1 cells, we sought to determine the effects of PKA on cell growth using thymidine incorporation assays. Exposure of Panc-1 cells to PGE 2 (1 mM) significantly decreased DNA synthesis. This effect was reversed by the EP4 receptor antagonist, while the EP2 receptor antagonist had no effect (Fig 4) . Activation of PKA by forskolin and IBMX resulted in a strong decrease of DNA synthesis in Panc-1 cells. Addition of the EP4 receptor antagonist to forskolin/IBMX significantly increased thymidine incorporation (Fig 4) . Again, PGE 2 had no effect on DNA synthesis in MIA PaCa-2 cells. In addition, EP2 and EP4 receptor antagonists failed to modulate DNA synthesis in MIA PaCa-2 cells, while forskolin/IBMX significantly decreased thymidine incorporation (Fig 4) .
High EP2 and low EP4 gene expression was correlated to worse overall median survival in patients with PDAC. Because our in vitro data suggested a potential protective (inhibitory) effect of EP4 receptors on PDAC growth, we sought to evaluate the expression of EP4 receptors and their correlation to survival of patients with PDAC. Gene expression patterns of PTGER2/4 in PDAC patient samples and their correlations with clinicopathologic variables were explored using a publicly available RNA-Seq data set (N = 183) from TCGA Research Network (http:// cancergenome.nih.gov/). We restricted our analysis to neoplasms with a histologic phenotype of adenocarcinoma and a tumor cell content of greater than 50% (N = 77) to evaluate tumor cell-specific gene expression to the relative exclusion of accompanying nonmalignant cell types (ie, benign pancreas, stroma, inflammation).
Tumors were segregated into groups of high versus low expression of PTGER2 or PTGER4 expression by k-means clustering. High versus low PTGER2 expression showed no significant correlation with survival (median overall survival 19.5 vs 20.8 months, log-rank P = .34, data not shown), while high versus low PTGER4 expression nearly reached significance (median overall survival 22.7 vs 19.5 months, log-rank P = .06, data not shown). Stratification based on combinations of PTGER2 and PTGER4 (groups 1-4, Fig 5, A) revealed that neoplasms with high PTGER2/low PTGER4 (group 3) were strongly correlated with worse overall survival relative to other subgroups (median overall survival 15.6 vs 20.8 months, log-rank P = .017, Fig 5, B) . No significant correlations were noted between high PTGER2/low PTGER4 and various clinicopathologic factors (Table) .
DISCUSSION
The cancer-promoting effects of COX-2 and COX-2-derived PGE 2 have been described in several studies. [3] [4] [5] [6] [7] [8] 12, 13 In PDAC, PGE 2 can stimulate COX-2 expression, constituting a positive feedback loop, which maintains a high production of prostanoids. 36 Further, PGE 2 promotes angiogenesis through VEGF, 30 fibrosis through activation of pancreatic stellate cells, 31 and inflammation, 13 all of which impact the tumor microenvironment, thereby emphasizing the crucial role it has on PDAC progression.
In our studies, we tested 2 human PDAC cell lines with different expression profiles of EP receptors. 34 While PGE 2 attenuated colony formation, DNA synthesis, and ERK phosphorylation in Panc-1 cells, it had no effect on MIA PaCa-2 cells. These results may be explained by the differential expression levels of EP2 and EP4 receptors in Panc-1 and MIA PaCa-2 cells. Our group described previously that expression levels of EP4 are multifold greater in Panc-1 than in MIA PaCa-2. EP2 is expressed at lower levels in both cell lines. 34 Our results provide evidence that the effects of PGE 2 in Panc-1 cells are mediated by the EP4 receptor. First, an EP4 but not EP2 receptor antagonist attenuated the PGE 2 -induced decrease Our observation is in contrast to other publications demonstrating that activation of G-coupled receptors with subsequent PKA activation promotes growth of several malignancies. [38] [39] [40] [41] Although the exact reasons for this discrepancy are unclear, differences in expression of EP receptors and distinct operative signaling networks in various cell lines might explain this finding. The proliferative effect of PKA-mediated activation of Ras-Raf-MEK-ERK can be regulated further by the GTPase Rap1, which is dependent on the absence or presence of B-Raf. While the presence of B-Raf leads to an enhancement of the Ras-Raf-MEK-ERK-pathway, in its absence, Rap1 will inhibit the Raf-1-MEK activation through Ras. 42, 43 In addition, ERK1/2 regulation by Ras and Rap depend on the type of stimulation (acute versus chronic). 44 Our in vitro data suggest clearly a potentially protective, growth-inhibitory effect of EP4 receptors in human PDAC. This notion seemingly is in contrast to the available literature describing a tumor-promoting effect of COX-2 and COX-2-derived PGE 2 . To our knowledge, however, a detailed analysis of the expression of EP receptors in human PDAC and its correlation to survival has not been conducted before. It is theoretically plausible that PGE 2 has a growth-inhibitory effect in a subgroup of human PDAC with high EP4 receptor expression (and, therefore, is correlated with a better prognosis).
This hypothesis is supported in part by the finding from another group describing varying expression of EP4 receptors in human PDAC using a tissue microarray containing 133 pancreatic tumor specimens along with 106 paired adjacent normal tissues. 45 Using the publicly available TCGA data set of 77 human PDAC (with a tumor cell content of >50%), we were able to confirm varying gene expression levels of EP4 (and EP2) receptors. More importantly, the combination of high EP2 and low EP4 gene expression was significantly associated with a worse overall median survival.
These data provide compelling evidence that EP4 receptors might have a protective effect in a subset of human PDAC. Moreover, our results emphasize the need to stratify human PDAC based on their expression of EP receptors to understand the effects of COX-2 and COX-2-derived PGE 2 on PDAC growth. This is equally important for the interpretation of clinical trials testing selective and nonselective COX-2 inhibitors aimed at decreasing PGE 2 levels.
In conclusion, we have shown that human PDAC cell lines respond differently to the major COX-2 metabolite, PGE 2 , and that PGE 2 can decrease growth, DNA synthesis, and ERK1/2-activation in Panc-1 through an EP4-PKA mediated pathway. In addition, high EP2 and low EP4 gene expression correlated to worse overall median survival in human PDAC. Our results provide evidence that EP4 receptors might have a protective effect in a subset of human PDAC.
